Back

Echocardiographic and biochemical evidences of cardioprotection by dapagliflozin in non-diabetic models exposed to sequential anthracyclines and trastuzumab therapy

11 December 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Role of echocardiography on cardio-oncology Myocardial Disease EACVI Premium Access EACVI 2025 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

5 More presentations in this session

Presentation thumbnail
Valvular heart disease in cancer patients - prevalence, relevance, and therapeutic management - preliminary results from the CESAR study
Doctor M. Autherith (Vienna, AT)
Abstract Slides
Presentation thumbnail
Comprehensive echocardiographic assessment of the diastolic cardiac function in children treated for acute lymphoblastic leukemia, preliminary results.
Doctor J. Haponiuk-Skwarlinska (Warsaw, PL)
Abstract Slides
Presentation thumbnail
The utility of serial global longitudinal strain and biomarkers in identifying subclinical cardiotoxicity in cancer patients receiving anthracycline or trastuzumab therapy
Doctor N. Shaaban (Alexandria, EG)
Abstract Slides
Presentation thumbnail
Dynamic cardiac toxicity monitoring in hematological tumor patients based on time thresholds and chemotherapy stratification
Doctor M. Zhang (Hangzhou, CN)
Abstract Slides
Presentation thumbnail
Thick but safe: revisiting the role of epicardial adipose tissue in chemotherapy-induced cardiac dysfunction
Assistant Professor H. Kim (Cheonan-si, KR)
Abstract Slides

Access the full session

Session thumbnail
Role of echocardiography on cardio-oncology

The Event

Event poster

EACVI 2025

11 December - 13 December 2025
You may be interested in
thumbnail
Congress Presentation
Echocardiography as first-line technique in suspected cardiac amyloidosis
thumbnail
Congress Presentation
Dilated cardiomyopathy
thumbnail
Congress Presentation
What is the best imaging method to assess myocardial viability? 

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources